Keyword: Shire

Shire R&D chief jumps ship to Ironwood spinout; Daiichi taps new CEO; and Kymab nabs new CEO from Merck KGaA.

With $225 million from TPG Capital and Vida Ventures and $10 million from its founders and board members, AskBio will ramp up clinical trials and manufacturing.

Rare disease biotech Cyclerion has poached Shire’s ex-head of R&D, Andy Busch, Ph.D., as its new chief innovation officer, less than 18 months after he joined the company from his long stint at Bayer.

Attune Pharmaceuticals raised $23 million in series B financing to push its oral drug for hereditary angioedema through phase 2.

The deal reunites some of the management team and investor syndicate that worked on the liver disease drug at Lumena before selling out to Shire.

Shire’s Steven Zhang, M.D., Ph.D., joined Kala Pharmaceuticals to lead its medical affairs work as it begins transitioning to the commercial stage.

In a move to bolster its access to plasma, Shire snapped up Swiss source plasma collection company Sanaplasma for an undisclosed price.